Remove 2010 Remove 2012 Remove Clinical Trials Remove Extraction
article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

In 2010, another pre-clinical study was also conducted on mice, and published in the American Journal of Hospice and Palliative Care. All these findings correlate with the conclusions of the scientists who were involved in the mice study from 2010. 16: Cannabis; June 2012, Pages 400-404. What is the best strain for ALS?

Strains 94
article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2012, the Journal of Neuropsychiatric Research reported that CB2 receptor activation attenuates blood-brain barrier damage in a rodent model of TBI.

THC 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Green Relief - Untitled Article

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2012, the Journal of Neuropsychiatric Research reported that CB2 receptor activation attenuates blood-brain barrier damage in a rodent model of TBI.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

years (Atakan 2012 ). Bostwick ( 2012 :174) notes that medical and recreational uses in the USA have now blended together and are becoming indistinguishable in the eyes of citizens. However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Safety is imperative for any reputable brand of hemp extract, and we are confident that the dosing we recommend is both safe and effective,” said Dr. Wakshlag, Chief Medical Officer at ElleVet Sciences. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,

Safety 45